BFRI (Biofrontera) Notes Receivable : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Biofrontera Notes Receivable?

Biofrontera's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.

Biofrontera Notes Receivable Historical Data

The historical data trend for Biofrontera's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera Notes Receivable Chart

Biofrontera Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Notes Receivable

Get a 7-Day Free Trial

Biofrontera Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Biofrontera Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Biofrontera Notes Receivable Related Terms

Thank you for viewing the detailed overview of Biofrontera's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Biofrontera Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera Inc (NAS:BFRI) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 Presidential Way, Suite 330, Woburn, MA, USA, 01801

Website

https://www.biofrontera-us.com

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.

Executives

Heikki Lanckriet	director	C/O BIOFRONTERA INC., 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Eugene Frederick Leffler	officer: Chief Financial Officer	84 BAY DRIVE, SUDBURY MA 01776
Kevin Daniel Weber	director	119 BUCHANAN COURT, CELINA TX 75009
Borer John J Iii	director	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Beth J. Hoffman	director	5895 BLAZING STAR LANE, SAN DIEGO CA 92130
Loretta M. Wedge	director	21260 WACISSA DRIVE, VENICE FL 34293
Ag Biofrontera	10 percent owner	HEMMELRATHER WEG 201, LEVERKUSEN 2M D-51377
Erica F. Gates	officer: Controller	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Erica L. Monaco	director, officer: Chief Financial Officer/COO	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Hermann Luebbert	director, officer: Chief Executive Officer	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801